Literature DB >> 25896717

Cerebral cavernous malformation (CCM) disease: from monogenic forms to genetic susceptibility factors.

E Trapani1, S F Retta.   

Abstract

Cerebral cavernous malformation (CCM) is a vascular disease of proven genetic origin, which may arise sporadically or can be inherited as autosomal dominant condition with incomplete penetrance and highly variable expressivity. CCM lesions manifest across a range of different phenotypes, including wide interindividual differences in lesion number, size and susceptibility to intracerebral hemorrhage (ICH), and may remain asymptomatic during the host's lifetime or result in pathological conditions of various type and severity at any age, with symptoms ranging from relatively minor (but still disabling) headaches through to very severe neurological deficits, seizures, and stroke. Currently, surgical removal of accessible lesions is the only direct therapeutic approach for CCM disease. However, whereas little information is available on the natural history of risk for patients to develop serious complications, such as ICH, prognostic biomarkers remain to be identified in order to ensure timely and optimal clinical decision making. In recent years, it has become clear that the three known CCM genes play an important role in controlling signalling pathways involved in cell responses to oxidative stress, pointing to a novel pathogenic mechanism whereby the function of CCM genes may be relevant in preventing vascular dysfunctions triggered by oxidative stress events. In turn, these novel findings have raised the possibility that genetic susceptibility factors related to differences in sensitivity to oxidative stress, including genetic polymorphisms, may contribute to interindividual differences in CCM disease susceptibility and severity. This review discusses recent progress toward the understanding of molecular mechanisms of pathogenesis and the identification of genetic susceptibility factors that could influence onset, progression and clinical severity of CCM disease, as well as consequent implications for the development of novel, safe and effective therapeutic strategies.

Entities:  

Mesh:

Year:  2015        PMID: 25896717

Source DB:  PubMed          Journal:  J Neurosurg Sci        ISSN: 0390-5616            Impact factor:   2.279


  14 in total

1.  PHACE syndrome is associated with intracranial cavernous malformations.

Authors:  Kimberly A Foster; William J Ares; Zachary J Tempel; Andrew A McCormick; Ashok Panigrahy; Lorelei J Grunwaldt; Stephanie Greene
Journal:  Childs Nerv Syst       Date:  2016-04-28       Impact factor: 1.475

Review 2.  Oxidative stress and inflammation in cerebral cavernous malformation disease pathogenesis: Two sides of the same coin.

Authors:  Saverio Francesco Retta; Angela J Glading
Journal:  Int J Biochem Cell Biol       Date:  2016-09-14       Impact factor: 5.085

Review 3.  The molecular basis of endothelial cell plasticity.

Authors:  Elisabetta Dejana; Karen K Hirschi; Michael Simons
Journal:  Nat Commun       Date:  2017-02-09       Impact factor: 14.919

4.  KRIT1 loss-of-function induces a chronic Nrf2-mediated adaptive homeostasis that sensitizes cells to oxidative stress: Implication for Cerebral Cavernous Malformation disease.

Authors:  Cinzia Antognelli; Eliana Trapani; Simona Delle Monache; Andrea Perrelli; Martina Daga; Stefania Pizzimenti; Giuseppina Barrera; Paola Cassoni; Adriano Angelucci; Lorenza Trabalzini; Vincenzo Nicola Talesa; Luca Goitre; Saverio Francesco Retta
Journal:  Free Radic Biol Med       Date:  2017-11-21       Impact factor: 7.376

Review 5.  Vitamin D Deficiency and the Risk of Cerebrovascular Disease.

Authors:  Hyun Ah Kim; Andrea Perrelli; Alberto Ragni; Francesca Retta; T Michael De Silva; Christopher G Sobey; Saverio Francesco Retta
Journal:  Antioxidants (Basel)       Date:  2020-04-17

Review 6.  Dicarbonyl Stress and S-Glutathionylation in Cerebrovascular Diseases: A Focus on Cerebral Cavernous Malformations.

Authors:  Cinzia Antognelli; Andrea Perrelli; Tatiana Armeni; Vincenzo Nicola Talesa; Saverio Francesco Retta
Journal:  Antioxidants (Basel)       Date:  2020-02-01

7.  KRIT1 Deficiency Promotes Aortic Endothelial Dysfunction.

Authors:  Francesco Vieceli Dalla Sega; Raffaella Mastrocola; Giorgio Aquila; Francesca Fortini; Claudia Fornelli; Alessia Zotta; Alessia S Cento; Andrea Perrelli; Enrica Boda; Antonio Pannuti; Saverio Marchi; Paolo Pinton; Roberto Ferrari; Paola Rizzo; Saverio Francesco Retta
Journal:  Int J Mol Sci       Date:  2019-10-05       Impact factor: 5.923

8.  Beyond multiple mechanisms and a unique drug: Defective autophagy as pivotal player in cerebral cavernous malformation pathogenesis and implications for targeted therapies.

Authors:  Saverio Marchi; Eliana Trapani; Mariangela Corricelli; Luca Goitre; Paolo Pinton; Saverio Francesco Retta
Journal:  Rare Dis       Date:  2016-01-25

Review 9.  Biological Activities, Health Benefits, and Therapeutic Properties of Avenanthramides: From Skin Protection to Prevention and Treatment of Cerebrovascular Diseases.

Authors:  Andrea Perrelli; Luca Goitre; Anna Maria Salzano; Andrea Moglia; Andrea Scaloni; Saverio Francesco Retta
Journal:  Oxid Med Cell Longev       Date:  2018-08-23       Impact factor: 6.543

10.  Cytochrome P450 and matrix metalloproteinase genetic modifiers of disease severity in Cerebral Cavernous Malformation type 1.

Authors:  Hélène Choquet; Eliana Trapani; Luca Goitre; Lorenza Trabalzini; Amy Akers; Marco Fontanella; Blaine L Hart; Leslie A Morrison; Ludmila Pawlikowska; Helen Kim; Saverio Francesco Retta
Journal:  Free Radic Biol Med       Date:  2016-01-19       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.